menu
    • menu

    Company profile for ProFound Therapeutics

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ProFound Therapeutics is at the forefront of pioneering a revolutionary approach to drug discovery through the comprehensive exploration of the human proteome. Leveraging their proprietary ProFoundry Platform, which employs cutting-edge protein detection technologies, the company systematically identifies and validates tens of thousands of novel proteins. This platform not only elucidates the connectivity and functionality of ...
    ProFound Therapeutics is at the forefront of pioneering a revolutionary approach to drug discovery through the comprehensive exploration of the human proteome. Leveraging their proprietary ProFoundry Platform, which employs cutting-edge protein detection technologies, the company systematically identifies and validates tens of thousands of novel proteins. This platform not only elucidates the connectivity and functionality of these proteins but also uncovers their potential therapeutic roles in various health conditions and diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ProFound TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    55 Cambridge Parkway · Suite 800E · Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.profoundtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/profoundtx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ProFound Therapeutics Names Chittenden as CTO, Laurel Ostrom CHRO
    ProFound Therapeutics Names Chittenden as CTO, Laurel Ostrom CHRO

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207543/0/en/ProFound-Therapeutics-Strengthens-Leadership-Team-with-Tom-Chittenden-as-Chief-Technology-Officer-and-Laurel-Ostrom-as-Chief-Human-Resources-Officer.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Flagship Signs ProFound, Quotient Deals in GSK Pact
    Flagship Signs ProFound, Quotient Deals in GSK Pact

    20 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/flagship-pioneering-announces-new-agreements-with-profound-therapeutics-and-quotient-therapeutics-under-its-collaboration-with-gsk-302621224.html

    PR NEWSWIRE
    20 Nov 2025
    Share Share
    Novartis Pens ProFound Pact for Cardiovascular Disease Targets
    Novartis Pens ProFound Pact for Cardiovascular Disease Targets

    27 Jun 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-pens-profound-pact-offering-750m-biobucks-cardiovascular-target

    FIERCE BIOTECH
    27 Jun 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    GSK Selects First Biotech Partners in $7B Flagship Deal

    Details:

    The collaboration aims to develop a protein-based therapy for chronic obstructive pulmonary disease (COPD).


    Lead Product(s): Undisclosed

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: DiscoveryProduct Type: Protein

    Sponsor: GSK

    Deal Size: $7,000.0 million Upfront Cash: $720.0 million

    Deal Type: Collaboration November 20, 2025

    blank

    01

    ProFound Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    ProFound Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Discovery

    Partner/Sponsor/Collaborator : GSK

    Deal Size : $7,000.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    GSK Selects First Biotech Partners in $7B Flagship Deal

    Details : The collaboration aims to develop a protein-based therapy for chronic obstructive pulmonary disease (COPD).

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : $720.0 million

    November 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis

    Details:

    The collaboration of ProFound with Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry Platform.


    Lead Product(s): Undisclosed

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Undisclosed

    Sponsor: Novartis Pharmaceuticals Corporation

    Deal Size: $775.0 million Upfront Cash: $25.0 million

    Deal Type: Collaboration June 26, 2025

    blank

    02

    ProFound Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    ProFound Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Discovery Platform

    Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation

    Deal Size : $775.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis

    Details : The collaboration of ProFound with Novartis to discover and develop novel therapeutics for cardiovascular disease leveraging its ProFoundry Platform.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : $25.0 million

    June 26, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Flagship Pioneering and ProFound Collaborate on First-in-Class Therapeutics for Obesity

    Details:

    ProFound will deploy its proprietary ProFoundry Platform in collaboration with Pioneering Medicines' expertise to discover novel proteins and evaluate their therapeutic relevance for obesity.


    Lead Product(s): Undisclosed

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Undisclosed

    Sponsor: Flagship Pioneering

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement June 12, 2024

    blank

    03

    ProFound Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed

    ProFound Therapeutics

    U.S.A
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Discovery Platform

    Partner/Sponsor/Collaborator : Flagship Pioneering

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Flagship Pioneering and ProFound Collaborate on First-in-Class Therapeutics for Obesity

    Details : ProFound will deploy its proprietary ProFoundry Platform in collaboration with Pioneering Medicines' expertise to discover novel proteins and evaluate their therapeutic relevance for obesity.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    June 12, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search